Objectives: To investigate the performance of the meropenem and imipenem double-ended Etest+EDTA and the tablet-based (meropenem and meropenem + dipicolinic acid) KPC/MBL Confirm Kit to detect cfiA metallob-lactamase (MBL) in Bacteroides fragilis.
Introduction
Metallo-b-lactamase (MBL) production encoded by the cfiA gene in Bacteroides fragilis is increasingly recognized in clinical isolates all over Europe. 1 -5 Prevalences as high as 38% (18 of 48) in clinical isolates have been reported from Turkey. 3 Lately, MDR B. fragilis, including metronidazole resistance and cfiA-mediated carbapenem resistance, has been reported in many patients. 2, 5 This emphasizes the need to monitor B. fragilis, which is the most frequent anaerobic bacteria in bacteraemia and a prevalent member of normal human gut flora, to uncover possible therapeutic problems. Although cfiA-positive B. fragilis produce an MBL, they can be low-level producers and still susceptible or intermediate to meropenem and/or imipenem according to EUCAST clinical breakpoints: susceptible, ≤2 mg/L; and resistant, .8 mg/L. 6, 7 The clinical consequences of low-level MBL production are largely unknown.
To detect or confirm MBL production a meropenem or imipenem double-ended Etest+EDTA (bioMérieux, La Balme-les-Grottes, France) is often used and an MIC ratio ≥8 is considered indicative of MBL production. 8, 9 Preliminary data from Bogaerts et al. 9 have already indicated that the imipenem double-ended Etest might not be optimal to detect MBL production in B. fragilis. It has been shown that B. fragilis isolates with the cfiA gene can be resistant to meropenem, but susceptible or intermediate to imipenem and have a negative imipenem double-ended Etest result, i.e. an MIC ratio ,8. More data are needed to confirm this and decide on the optimal strategy for MBL detection. 9 ROSCO Diagnostica (Taastrup, Denmark) has developed a KPC/ MBL Confirm Kit, primarily for the detection or confirmation of potential Klebsiella pneumoniae carbapenemase (KPC) or MBL production in Enterobacteriaceae. 10 The kit contains tablets with meropenem 10 mg (MRP10 -abbreviation printed on the tablets), meropenem 10 mg + boronic acid, meropenem 10 mg + cloxacillin and meropenem 10 mg + dipicolinic acid (MRPDPabbreviation printed on the tablets). A difference in zone diameter between meropenem and meropenem + dipicolinic acid of ≥5 mm (MRPDP.MRP10) is indicative of MBL production in Enterobacteriaceae. 10 No systematic studies with the KPC/MBL Confirm Kit and B. fragilis have been published so far, except as a meeting abstract. 11 The purpose of this study was to investigate the performance of the meropenem and imipenem double-ended Etest+EDTA and the tablet-based KPC/MBL Confirm Kit to detect cfiA MBL in B. fragilis. Schwensen et al.
Materials and methods
Well-characterized B. fragilis isolates, most from previously published studies, harbouring the cfiA gene and covering a wide range of meropenem MICs were included in the study (n ¼21). 6, 12 Four isolates were resistant and 17 isolates were susceptible to imipenem (Table 1) . B. fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 were also included. Gradient strip MICs with meropenem (Oxoid, Basingstoke, UK) and imipenem (bioMé rieux), including the double-ended Etest+EDTA were determined. The KPC/MBL Confirm Kit was tested with the same strains, but also with 22 randomly selected clinical B. fragilis isolates without the cfiA gene to determine specificity. All tests were performed on supplemented Brucella blood agar (Becton Dickinson, Heidelberg, Germany) with a McFarland 1 suspension in saline. Plates were incubated for 24 h in an anaerobic atmosphere (Anoxomat jar system; MART Microbiology, Drachten, the Netherlands).
Results
Results are presented in Table 1 . The imipenem double-ended Etest showed an indeterminate result in 95% of the included isolates with the cfiA gene (20 of 21), whereas the meropenem double-ended Etest gave an MIC ratio ≥8 with all the isolates. The 22 randomly selected clinical B. fragilis isolates without the cfiA gene were not tested with the double-ended Etests.
Eighteen of 21 isolates with the cfiA gene displayed a zone diameter difference of ≥5 mm between tablets with and without dipicolinic acid, resulting in a sensitivity of 85.7% (all isolates that were meropenem intermediate or resistant had a zone diameter difference ≥6 mm). The remaining 26 B. fragilis isolates (3 with the cfiA gene and 23 without) were ,5 mm resulting in a specificity of 100%. Lowering the zone diameter difference cut-off to ≥4 mm increased the sensitivity to 100%. Zone diameter differences tended to increase with increasing meropenem MICs.
Discussion
The results from the preliminary work by Bogaerts et al.
9 are supported by this study. Most isolates with the cfiA gene had an indeterminate result with the imipenem double-ended Etest although some isolates displayed a possible deformation of zone and/or microcolonies. In contrast, the results with the meropenem double-ended Etest were straightforward, even in isolates with meropenem MICs as low as 0.5 mg/L, which is susceptible according to EUCAST (susceptible ≤2 mg/L). Consequently, the meropenem double-ended Etest and not imipenem should be preferred for the phenotypic detection of MBLs in B. fragilis.
The ROSCO KPC/MBL Confirm Kit detected all MBL producing B. fragilis isolates with a zone diameter difference breakpoint of 4 mm, although this cut-off might be too small as one of the cfiA-negative B. fragilis isolates displayed a zone diameter difference of 3 mm. In cases of small zone diameter differences, the analysis should be supplemented with the more expensive meropenem double-ended Etest.
Areas that need to be addressed are the clinical implications of low-level MBL production and MICs below the EUCAST clinical breakpoints and the possible use of imipenem in imipenemsusceptible, but meropenem-resistant, B. fragilis isolates? So far clinical data are limited mainly because cfiA status has been unknown. In vitro experiments and case reports have demonstrated that resistant isolates can be selected after carbapenem exposure, which makes it clinically important to determine the relevance of the cfiA gene and MBL production. 13, 14 With the described methods MBL production can easily be demonstrated, which will make it possible to collect clinical information and investigate and compare cases and isolates with and without MBL production.
A rational approach would be to test all B. fragilis isolates with MICs above the meropenem epidemiological cut-off value (ECOFF), which is 0.25 mg/L for B. fragilis (EUCAST: www.eucast.org/ mic_distributions_and_ecoffs/). The meropenem double-ended Etest should be preferred for the detection of MBL, but the KPC/MBL Confirm Kit could be an alternative with isolates that are meropenem intermediate or resistant (MIC .2 mg/L).
